Who are Placebo to Baloxavir Marboxil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Baloxavir Marboxil tablets, Ten-days oseltamivir + baloxavir marboxil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-baloxavir-marboxil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo to Baloxavir Marboxil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Baloxavir Marboxil (Placebo to Baloxavir Marboxil) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cap-dependent endonuclease inhibitor. Area: Infectious Disease / Virology.

phase 3 Cap-dependent endonuclease inhibitor Influenza virus PA endonuclease (cap-dependent endonuclease) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Baloxavir Marboxil (Placebo to Baloxavir Marboxil) — Shionogi. Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus polymerase, preventing viral mRNA synthesis and replication.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Baloxavir Marboxil TARGET	Placebo to Baloxavir Marboxil	Shionogi	phase 3	Cap-dependent endonuclease inhibitor	Influenza virus PA endonuclease (cap-dependent endonuclease)
Baloxavir Marboxil tablets	Baloxavir Marboxil tablets	Jiaxing AnDiCon Biotech Co.,Ltd	phase 3	Cap-dependent endonuclease inhibitor	Influenza PA endonuclease
Ten-days oseltamivir + baloxavir marboxil	Ten-days oseltamivir + baloxavir marboxil	UMC Utrecht	phase 3	Neuraminidase inhibitor and cap-dependent endonuclease inhibitor	Neuraminidase and cap-dependent endonuclease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cap-dependent endonuclease inhibitor class)

Jiaxing AnDiCon Biotech Co.,Ltd · 1 drug in this class
Shionogi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Baloxavir Marboxil — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-baloxavir-marboxil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab